Cutting force measurement of electrical jigsaw by strain gauges

L

Micromechanical Properties of Injection-Molded Starch–Wood Particle Composites

The micromechanical properties of injection molded starch–wood particle composites were investigated as a function of particle content and humidity conditions. The composite materials were characterized by scanning electron microscopy and X-ray diffraction methods. The microhardness of the composites was shown to increase notably with the concentration of the wood particles. In addition,creep behavior under the indenter and temperature dependence were evaluated in terms of the independent contribution of the starch matrix and the wood microparticles to the hardness value. The influence of drying time on the density and weight uptake of the injection-molded composites was highlighted. The results revealed the role of the mechanism of water evaporation, showing that the dependence of water uptake and temperature was greater for the starch–wood composites than for the pure starch sample. Experiments performed during the drying process at 70°C indicated that the wood in the starch composites did not prevent water loss from the samples.Peer reviewe

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

A terhelt vallomása mint bizonyítási eszköz a büntetőeljárásban

A büntetőeljárásban a terhelt kétségkívül a legfontosabb résztvevő. Terhelt nélkül – bizonyos speciális helyzetek kivételével – nem is beszélhetünk büntetőeljárásról, hiszen ennek az eljárástípusnak pontosan az a lényege, hogy megállapítsa, hogy egy bizonyos személyt terhel-e büntetőjogi felelősség. Nagyrészt ez a tény indokolta, hogy a szakdolgozatomhoz ennek a témának a feldolgozását választottam.egységes, osztatlanJogás

A diclofenac hatásosságának vizsgálata praeemptív analgeticumként postcraniotomiás fejfájásban (randomizált, kontrollált, prospektív tanulmány)

Tanulmányi rendszerbe betöltv

A diclofenac hatásosságának vizsgálata praeemptív analgeticumként postcraniotomiás fejfájásban (randomizált, kontrollált, prospektív tanulmány)

Programfüzet: 38. oldal/ E38. A diclofenac hatásosságának vizsgálata praeemptiv analgeticumként postcraniotomiás fejfájásban (randomizált, placebo kontrollált, prospektiv tanulmány) Kazup Ágota, Simon Éva, Gál Judit, Siró Péter, Molnár Csilla, Fülesdi Béla Debreceni Egyetem OEC Aneszteziológiai és Intenzív Terápiás Tanszék,DebrecenTanulmányi rendszerbe betöltv